| Bioactivity | Ipafricept (OMP-54F28; FZD8-Fc) is the first class of recombinant fusion proteins, consisting of the extracellular portion of the human fried-8 receptor fused to the Fc fragment of human IgG1 binding to the Wnt ligand. Ipafricept shows solid tumor inhibition activity, with well tolerance[1]. |
| Target | Wnt ligand |
| Name | Ipafricept |
| CAS | 1391727-24-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jimeno A, et al. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. |